Related Experiment Video
Updated: Feb 21, 2026
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Immediate and Sustained Effects of Intensive Equine-Assisted Physiotherapy Based on Neuroproprioceptive "Facilitation
Katerina Marikova1, Jindra Reissigova2, Miloslav Vilimek3
1Department of Rehabilitation, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Ruská 87, Prague, 100 00, Czech Republic, 420604511416.
Insights
This study evaluates NEUROEQUIP-SMA, an innovative equine-assisted physiotherapy, for children with spinal muscular atrophy (SMA). Results will determine if this method improves motor development and quality of life compared to standard therapy.
Area of Science:
- Neurology
- Pediatrics
- Rehabilitation Medicine
Background:
- Spinal muscular atrophy (SMA) is a rare genetic neuromuscular disease impacting infant survival and motor function.
- Pharmacological treatments enhance survival and function, but physiotherapy remains crucial for SMA care.
- NEUROEQUIP-SMA, a novel equine-assisted physiotherapy, utilizes neuroproprioceptive principles to potentially improve motor development in children with SMA.
Purpose of the Study:
- To assess the efficacy of NEUROEQUIP-SMA against standard physiotherapy (SMA-SOC-N) in children with SMA.
- To evaluate the impact of NEUROEQUIP-SMA on functional outcomes and quality of life (QoL).
- To analyze the response of molecular biomarkers to both treatment protocols.
Main Methods:
- A crossover randomized controlled trial involving 20 children (ages 2-9) with SMA types I-III.
- Participants undergo two 6-day therapy programs (NEUROEQUIP-SMA and SMA-SOC-N) separated by a 10-week washout period.
- Primary outcome: CHOP INTEND score; Secondary outcomes: motor coordination, muscle fatigue, spirometry, psychomotor development, and QoL.
Main Results:
- Data collection scheduled for Feb-May 2026, with results expected in 2027.
- Statistical power analysis indicates ability to detect moderate-to-large effect sizes for the primary outcome.
- Study aims to report treatment effect sizes alongside P values to quantify changes.
Conclusions:
- This trial is the first to investigate NEUROEQUIP-SMA for children with SMA.
- If effective, NEUROEQUIP-SMA could offer a valuable complementary therapy for children with SMA.
- This approach may significantly enhance care for children undergoing gene therapy for SMA.
Background:
Spinal muscular atrophy (SMA) is a rare neuromuscular disease and the most common genetic cause of infant death. Although pharmacological treatment improves survival rates and functional capacity, physiotherapy remains a key component of care. A newly developed innovative equine-assisted physiotherapy method based on neuroproprioceptive "facilitation and inhibition" principles (NEUROEQUIP-SMA) is hypothesized to improve the quality and extent of motor development in children with SMA.
Objective:
The aim of this study is to assess the efficacy of NEUROEQUIP-SMA compared with standard individual outpatient physiotherapy based on the same neuroproprioceptive "facilitation and inhibition" principles (SMA-SOC-N) and to evaluate its effects on functional outcomes and quality of life (QoL). In addition, the response of molecular biomarkers to treatment will be assessed.
Methods:
In this crossover randomized controlled trial, 20 children with SMA types I-III, aged 2-9 years, will participate in two 6-day therapy programs (A and B) of equal duration (50 min per day) and separated by a 10-week washout period. Each child will be randomly assigned to receive the therapies in either the AB or BA sequence. Therapy A consists of a newly developed NEUROEQUIP-SMA (15 min twice daily), whereas therapy B involves SMA-SOC-N (30 min once daily). Both programs include therapeutic horse grooming (20 min a day). The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND) was selected as the primary outcome measure. Secondary outcomes included motor coordination assessed through 3D motion analysis, muscle fatigue, spirometry, and standardized clinical tests and rating scales, as well as monitoring of psychomotor development (via home-video analysis) and QoL (via questionnaires). Molecular biomarkers will be analyzed from blood samples. The immediate effect of the intervention will be evaluated for most outcomes, while psychomotor development and QoL will be monitored 28 days after therapy as longer-term outcomes. Treatment effect sizes will be reported alongside P values to illustrate the magnitude of changes in the outcomes. The study was approved by the Ethics Committee of the Third Faculty of Medicine, Charles University, under the number UK3LF/658559/12025.
Results:
The study is designed for 20 participants. Data collection will begin in February 2026 and will be completed in May 2026. Data analyses are planned for autumn 2026, and study results are expected to be available in 2027. A paired t test comparing the primary outcome (CHOP INTEND) between treatments NEUROEQUIP-SMA and SMA-SOC-N in 20 children will have 80% power to detect moderate-to-large effect size (Cohen d=0.66) at a 5% significance level.
Conclusions:
This trial will be the first study to evaluate the effects of NEUROEQUIP-SMA in children with SMA. If preliminary findings confirm a benefit, this physiotherapy approach may represent a promising adjunct to care for the generation of children undergoing gene therapy.
More Related Videos
05:04Enhancing the Development and Growth of Infant Cerebral Palsy Rats Using Selective Spinal Manipulations
Published on: February 2, 2024
10:08The Evoked Potential Operant Conditioning System EPOCS: A Research Tool and an Emerging Therapy for Chronic Neuromuscular Disorders
Published on: August 25, 2022